When 12-year-old Mateo began losing weight and suffering relentless abdominal pain, his parents feared the worst. In Boston, doctors at Beth Israel Deaconess Medical Center and Mass General Brigham for Children ran a battery of tests, but instead of rushing to an invasive endoscopy, they turned to a breakthrough blood test still in development—one that could change how children like Mateo are diagnosed with inflammatory bowel disease (IBD). Researchers led by Dr. Towia Libermann and Dr. Harland Winter have identified a four-protein signature in the blood that can detect pediatric IBD with 80% to 90% accuracy, offering hope for a future where painful, costly procedures are no longer the first step in diagnosis.
For years, diagnosing IBD in children has relied heavily on endoscopies and biopsies—stressful, invasive procedures that delay treatment and increase anxiety for young patients and their families. While noninvasive tools like stool tests exist, none have been precise enough to stand alone. Now, using advanced proteomics to analyze over 1,300 proteins in blood samples, the Boston team has uncovered patterns invisible to conventional methods. In an initial cohort of 47 children, they found 95 proteins elevated in those with IBD and 70 that helped differentiate between Crohn’s disease and ulcerative colitis. With machine learning, they distilled this complex signal into just eight proteins, then further refined it to a practical four-protein panel.
The real test came when they validated this signature in two larger groups—295 and 105 children respectively—using standard laboratory techniques already available in hospitals. The results were striking: the four-protein test not only identified IBD with high accuracy but also distinguished between Crohn’s and ulcerative colitis with over 90% predictive performance. This level of precision could allow doctors to start targeted therapies sooner, reducing the diagnostic odyssey that often stretches for months. Beyond diagnosis, the protein patterns shed light on the biological mechanisms driving each form of IBD, opening doors to personalized treatments based on a child’s unique molecular profile.
"A validated blood-based diagnostic approach could help reduce diagnostic delays, minimize invasive procedures, and support earlier, more personalized treatment decisions for children with IBD," said Dr. Libermann, whose team’s work was published in eBioMedicine. While the test is not yet ready for routine use, its validation in real-world clinical samples marks a major leap forward. For families navigating the uncertainty of chronic illness, the promise of a simple blood draw replacing sedation and scopes is more than a medical advance—it’s a relief. As research continues, this proteomic signature may soon become a standard tool, transforming not just diagnosis, but the entire journey of care for children with IBD.